Top

Published in:

01-10-2011 | Research Article

PET Imaging of Hypoxia-Inducible Factor-1-Active Tumor Cells with Pretargeted Oxygen-Dependent Degradable Streptavidin and a Novel ¹⁸F-Labeled Biotin Derivative

Authors: Takashi Kudo, Masashi Ueda, Hiroaki Konishi, Hidekazu Kawashima, Yuji Kuge, Takahiro Mukai, Azusa Miyano, Shotaro Tanaka, Shinae Kizaka-Kondoh, Masahiro Hiraoka, Hideo Saji

Published in: Molecular Imaging and Biology | Issue 5/2011

Abstract

Purpose

We aimed to evaluate the feasibility of using streptavidin–biotin-based pretargeting for positron emission tomography (PET) imaging of hypoxia-inducible factor (HIF)-1-active tumors.

Procedures

We used POS, a genetically engineered form of streptavidin that selectively stabilizes in HIF-1-active cells, and (4-¹⁸F-fluorobenzoyl)norbiotinamide (¹⁸F-FBB), a radiolabeled biotin derivative, for performing a biodistribution study and for PET imaging. The tumoral ¹⁸F-FBB accumulation was compared to the HIF-1-dependent luciferase bioluminescence and HIF-1α immunohistochemical signal.

Results

¹⁸F-FBB accumulation was observed in POS-pretargeted tumors in mice (2.85 ± 0.55% injected dose per gram at 3 h), and clear PET images were obtained at the same time point. The tumoral ¹⁸F-FBB accumulation positively correlated with luciferase bioluminescence (R = 0.72, P < 0.05), and most of the area showing ¹⁸F-FBB accumulation corresponded to HIF-1α-positive areas.

Conclusion

Pretargeting with POS and ¹⁸F-FBB is an effective approach for PET imaging of HIF-1-active areas in tumors.

Available only for authorised users

Vaupel P, Kallinowski F, Okunieff P (1989) Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 49:6449–6465PubMed

Brown JM (2000) Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today 6:157–162PubMedCrossRef

Hockel M, Vaupel P (2001) Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 93:266–276PubMedCrossRef

Semenza GL (2007) Life with oxygen. Science 318:62–64PubMedCrossRef

Semenza GL (2003) Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3:721–732PubMedCrossRef

Dewhirst MW, Cao Y, Moeller B (2008) Cycling hypoxia and free radicals regulate angiogenesis and radiotherapy response. Nat Rev Cancer 8:425–437PubMedCrossRef

Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci U S A 92:5510–5514PubMedCrossRef

Harada H, Kizaka-Kondoh S, Li G et al (2007) Significance of HIF-1-active cells in angiogenesis and radioresistance. Oncogene 26:7508–7516PubMedCrossRef

Harada H, Kizaka-Kondoh S, Hiraoka M (2005) Optical imaging of tumor hypoxia and evaluation of efficacy of a hypoxia-targeting drug in living animals. Mol Imaging 4:182–193PubMed

10.

Kizaka-Kondoh S, Konse-Nagasawa H (2009) Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci 100:1366–1373PubMedCrossRef

11.

Kizaka-Kondoh S, Tanaka S, Harada H, Hiraoka M (2009) The HIF-1-active microenvironment: an environmental target for cancer therapy. Adv Drug Deliv Rev 61:623–632PubMedCrossRef

12.

Kudo T, Ueda M, Kuge Y et al (2009) Imaging of HIF-1-active tumor hypoxia using a protein effectively delivered to and specifically stabilized in HIF-1-active tumor cells. J Nucl Med 50:942–949PubMedCrossRef

13.

Ueda M, Kudo T, Kuge Y et al (2010) Rapid detection of hypoxia-inducible factor-1-active tumours: pretargeted imaging with a protein degrading in a mechanism similar to hypoxia-inducible factor-1α. Eur J Nucl Med Mol Imaging 37:1566–1574PubMedCrossRef

14.

Shoup TM, Fischman AJ, Jaywook S, Babich JW, Strauss HW, Elmaleh DR (1994) Synthesis of fluorine-18-labeled biotin derivatives: biodistribution and infection localization. J Nucl Med 35:1685–1690PubMed

15.

Vaidyanathan G, Zalutsky MR (2006) Synthesis of N-succinimidyl 4-[¹⁸F]fluorobenzoate, an agent for labeling proteins and peptides with ¹⁸F. Nat Protoc 1:1655–1661PubMedCrossRef

16.

Hara T, Higashi T, Nakamoto Y et al (2009) Significance of chronic marked hyperglycemia on FDG-PET: is it really problematic for clinical oncologic imaging? Ann Nucl Med 23:657–669PubMedCrossRef

17.

Ono M, Watanabe R, Kawashima H et al (2009) Fluoro-pegylated chalcones as positron emission tomography probes for in vivo imaging of beta-amyloid plaques in Alzheimer’s disease. J Med Chem 52:6394–6401PubMedCrossRef

18.

Kimura H, Tomatsu K, Kawashima H et al (2009) Development of one-flow synthesis method for N-succinimidyl 4-[F-18]fluorobenzoate ([F-18]SFB) using microreactor for 3-step-reaction. J Label Compd Radiopharm 52:S9–S9

19.

Tang G, Zeng WB, Yu MX, Kabalka G (2008) Facile synthesis of N-succinimidyl 4-[F-18]fluorobenzoate ([F-18]SFB) for protein labeling. J Label Compd Radiopharm 51:68–71CrossRef

20.

Kizaka-Kondoh S, Itasaka S, Zeng L et al (2009) Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer. Clin Cancer Res 15:3433–3441PubMedCrossRef

21.

Ueda M, Iida Y, Tominaga A et al (2010) Nicotinic acetylcholine receptors expressed in the ventralposterolateral thalamic nucleus play an important role in anti-allodynic effects. Br J Pharmacol 159:1201–1210PubMedCrossRef

22.

Picchio M, Beck R, Haubner R et al (2008) Intratumoral spatial distribution of hypoxia and angiogenesis assessed by ¹⁸F-FAZA and ¹²⁵I-Gluco-RGD autoradiography. J Nucl Med 49:597–605PubMedCrossRef

23.

Krohn KA, Link JM, Mason RP (2008) Molecular imaging of hypoxia. J Nucl Med 49 Suppl 2:129S–148SPubMedCrossRef

24.

Mees G, Dierckx R, Vangestel C, Van de Wiele C (2009) Molecular imaging of hypoxia with radiolabelled agents. Eur J Nucl Med Mol Imaging 36:1674–1686PubMedCrossRef

25.

Dunphy MP, Lewis JS (2009) Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. J Nucl Med 50 Suppl 1:106S–121SPubMedCrossRef

26.

Lehmann S, Stiehl DP, Honer M et al (2009) Longitudinal and multimodal in vivo imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci U S A 106:14004–14009PubMedCrossRef

27.

Oh M, Tanaka T, Kobayashi M et al (2009) Radio-copper-labeled Cu-ATSM: an indicator of quiescent but clonogenic cells under mild hypoxia in a Lewis lung carcinoma model. Nucl Med Biol 36:419–426PubMedCrossRef

28.

Chauhan J, Dakshinamurti K (1986) Purification and characterization of human serum biotinidase. J Biol Chem 261:4268–4275PubMed

29.

Foulon CF, Alston KL, Zalutsky MR (1997) Synthesis and preliminary biological evaluation of (3-iodobenzoyl)norbiotinamide and ((5-iodo-3-pyridinyl)carbonyl)norbiotinamide: two radioiodinated biotin conjugates with improved stability. Bioconjug Chem 8:179–186PubMedCrossRef

30.

Liu RS, Chou TK, Chang CH et al (2009) Biodistribution, pharmacokinetics and PET imaging of [¹⁸F]FMISO, [¹⁸F]FDG and [¹⁸F]FAc in a sarcoma- and inflammation-bearing mouse model. Nucl Med Biol 36:305–312PubMedCrossRef

31.

Serganova I, Doubrovin M, Vider J et al (2004) Molecular imaging of temporal dynamics and spatial heterogeneity of hypoxia-inducible factor-1 signal transduction activity in tumors in living mice. Cancer Res 64:6101–6108PubMedCrossRef

32.

Hsieh CH, Kuo JW, Lee YJ, Chang CW, Gelovani JG, Liu RS (2009) Construction of mutant TKGFP for real-time imaging of temporal dynamics of HIF-1 signal transduction activity mediated by hypoxia and reoxygenation in tumors in living mice. J Nucl Med 50:2049–2057PubMedCrossRef

33.

Wen B, Burgman P, Zanzonico P et al (2004) A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia. Eur J Nucl Med Mol Imaging 31:1530–1538PubMedCrossRef

34.

Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ (1999) Evaluation of ⁶⁴Cu-ATSM in vitro and in vivo in a hypoxic tumor model. J Nucl Med 40:177–183PubMed

35.

Piert M, Machulla HJ, Picchio M et al (2005) Hypoxia-specific tumor imaging with ¹⁸F-fluoroazomycin arabinoside. J Nucl Med 46:106–113PubMed

36.

Dakshinamurti K, Chauhan J, Ebrahim H (1987) Intestinal absorption of biotin and biocytin in the rat. Biosci Rep 7:667–673PubMedCrossRef

37.

Hainsworth J, Harrison P, Mather SJ (2005) Preparation and characterization of a DOTA–lysine–biotin conjugate as an effector molecule for pretargeted radionuclide therapy. Bioconjug Chem 16:1468–1474PubMedCrossRef

Title: PET Imaging of Hypoxia-Inducible Factor-1-Active Tumor Cells with Pretargeted Oxygen-Dependent Degradable Streptavidin and a Novel 18F-Labeled Biotin Derivative
Authors: Takashi Kudo
Masashi Ueda
Hiroaki Konishi
Hidekazu Kawashima
Yuji Kuge
Takahiro Mukai
Azusa Miyano
Shotaro Tanaka
Shinae Kizaka-Kondoh
Masahiro Hiraoka
Hideo Saji
Publication date: 01-10-2011
Publisher: Springer-Verlag
Published in: Molecular Imaging and Biology / Issue 5/2011
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI: https://doi.org/10.1007/s11307-010-0418-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

PET Imaging of Hypoxia-Inducible Factor-1-Active Tumor Cells with Pretargeted Oxygen-Dependent Degradable Streptavidin and a Novel ¹⁸F-Labeled Biotin Derivative

Abstract

Purpose

Procedures

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Procedures

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 5/2011

Synthesis and Evaluation of 99mTc-Labelled Monoclonal Antibody 1D09C3 for Molecular Imaging of Major Histocompatibility Complex Class II Protein Expression

Erratum to: Intraoperative Multispectral Fluorescence Imaging for the Detection of the Sentinel Lymph Node in Cervical Cancer: A Novel Concept

Determinants of Physiologic 18F-FDG Uptake in Brown Adipose Tissue in Sequential PET/CT Examinations

A Portable Fluorescence Camera for Testing Surgical Specimens in the Operating Room: Description and Early Evaluation

Correlation Between Epidermal Growth Factor Receptor-Specific Nanobody Uptake and Tumor Burden: A Tool for Noninvasive Monitoring of Tumor Response to Therapy

Quantitative Assessment of Diffusion-Weighted MR Imaging in Patients with Primary Rectal Cancer: Correlation with FDG-PET/CT